尼妥珠单抗联合顺铂同步放化疗治疗中晚期鼻咽癌的近期疗效

目的探讨尼妥珠单抗联合顺铂同步放化疗治疗中晚期鼻咽癌的临床效果。方法随机抽取我院2009-2012年收治的54例中晚期鼻咽癌患者,根据治疗方法的不同分为对照组和观察组,每组27例,对照组采用顺铂同步放化疗治疗,观察组在顺铂同步放化疗治疗的基础上加以尼妥珠单抗联合治疗,治疗后观察和评价两组患者的治疗效果。结果对照组和观察组的治疗总有效率分别为74.1%和96.3%,观察组明显高于对照组,差异具有统计学意义（P〈0.05）。观察组治疗过程中各种不良反应如心电图异常、消化道反应、脱发、发热、中性粒细胞减少、红细胞减少、血小板减少应的发生率均显著低于对照组（P〈0.05）。结论尼妥珠单抗联合顺铂同步放化疗治疗局部晚期鼻咽癌的疗效显著,优于单纯同步放化疗,且毒副作用更少,安全性高,值得临床推广与应用。

Nimotuzumab Concurrent Radiotherapy and Cisplatin Chemotherapy in Advanced Nasopharyngeal Carcinoma

Objective To investigate the effect of nimotuzumab with concurrent cisplatin radiochemotherapy on advanced nasopharyngeal carcinoma. Methods A total of 54 patients with advanced nasopharyngeal carcinoma in our hospital between 2009 and 2012 were randomly divided into control group and observation group, and each group had 27 cases. The control group were treated with concurrent cisplatin radiochemotherapy, and the observation group were treated with nimotuzumab combined with concurrent cisplatin radiochemotherapy. After treatment, the therapeutic effect of two groups were observed and evaluated. Results The total effective rate was 74.1% in the control group and 96.3% in the observation group, which was significantly higher in observation group. The difference was statistically significant（P0.05）. During the treatment group, the incidence of adverse reactions such as ECG abnormalities, gastrointestinal reactions, hair loss, fever, neutropenia, red blood cells, thrombocytopenia was significantly lower in observation group than in the control group（P0.05）. Conclusion Nimotuzumab combined with concurrent cisplatin chemoradiotherapy had significantly better effect on the locally advanced nasopharyngeal carcinoma than concurrent chemoradiotherapy, and had fewer side effects. It was safe and worthy of clinical application.